Cancer Science and Targeted Therapy Conference

September 06-08, 2021

Melbourne Cricket Ground
Olympic Room Locked Bag 6 East
Melbourne, 8002, Australia
The meeting aims to bring together the pioneers in both basic and translational cancer research and cover the research studies discovering the genes affect cancer risk and the genomics; fundamentals of cancer cells and the hormone responses, cancer-controlling proteins, cell signaling and growth, novel diagnostic methods, new-generation molecular targeted therapies and immune treatments.

Cancer Therapy 2021 scientific meeting on September 06-08, 2021 at Melbourne

Committee Members

Marco Falasca
Conference Chair
Curtin University
Perth

Kenny Chitcholtan
University of Otago
Christchurch
New Zealand

Ygal Haupt
Peter Mac Callum Cancer Centre
Melbourne, Australia

Khosrow Kashfi
The City College of New York
NY, USA

Suresh Ambudkar
NCI/NIH
MD, USA

Scientific Sessions

♦ Cancer Metastasis and Biology
♦ Targeted Cancer Therapies
♦ Cancer Immunotherapies
♦ Growth Factor Signalling in Cancer
♦ Lipid Signalling in Cancer
♦ Extracellular Vesicles in Cancer
♦ Cancer Microenvironment
♦ Cancer Stem Cells
♦ Cancer Genetics and Biomarkers
♦ Novel Therapeutics Target For Cancer
♦ Cancer Chemotherapy, Resistance and Prevention
♦ Breast Cancer
♦ Lung Cancer
♦ Cancer Epidemiology
Conference Introduction

Session-1  Chemoresistance

**To Trick a Transporter: Targeting Lysosomal P-glycoprotein with Innovative Multi-functional Anti-tumour Agents**  
Des R. Richardson, University of Sydney, New South Wales, Australia

**Cancer Chemoresistance and ABC Drug Transporters**  
Suresh V. Ambudkar, NCI/NIH, MD, USA

**Why do we need to know where drugs bind on P-gp?**  
Richard Callaghan, The Australian National University, Canberra, Australia

Coffee Break

Session-2  Growth Factor Signalling

**c-Met Activation Leads to the Establishment of a TGFβ-receptor Regulatory Network Required for Bladder Cancer Invasion**  
Pieter Eichhorn, Curtin University, Perth, Australia

**Targeting Protein Synthesis and Growth Signalling in Prostate Cancer**  
Luc Furic, Monash University, Melbourne, Australia

**The TWEAK/Fn14 Pathway as a Therapeutic Target in Hepatocellular Carcinoma and Cholangiocarcinoma**  
Nina Tirnitz-Parker, Curtin Health Innovation Research Institute, Perth, Australia

**Sensitivity of EGFR/HER-2 Positive Cells Isolated from Ascitic Fluid of Advanced Ovarian Cancer Patients to EGFR/HER-2 Inhibitors**  
Kenny Chitcholtan, University of Otago, Christchurch, New Zealand

Lunch Break

Session-3  Lipid Signalling

**Targeting Sphingolipid Metabolism in Acute Myeloid Leukemia**  
Stuart Pitson, University of South Australia and SA Pathology, Adelaide, Australia

**Regulation of Phosphoinositide 3-kinase Signaling in Breast Cancer**  
Christina Mitchell, Monash University, Melbourne, Australia

**Class II Phosphoinositide 3-kinase β and Cancer: A Novel Therapeutic Target?**  
Tania Maffucci, Queen Mary University of London, UK

**Characterising Roles of the PTEN-PI3K Axis in Breast Tumorigenesis**  
Antonella Papa, Monash University, Melbourne, Australia
Identifying Optimal Strategies to Target S1P Signaling for the Attenuation of Cancer Progression and Chemotherapeutic Toxicity
Deron R. Herr, National University of Singapore, Singapore

Session-4 Extracellular Vesicles

Remote Control of Neuroblastoma Metabolism, Proliferation and Gene Expression through MYCN-Regulated Extracellular Vesicles
Arturo Sala, Brunel University London, UK

Pancreatic Cancer: Perspectives for a Brighter Prognosis
Marco Falasca, Curtin University, Perth, Australia

Exosomes Orchestrate Fibroblast-led Cancer Invasion – New Insights into Cancer Signalling
David Greening, Baker Heart and Diabetes Institute, Melbourne, Australia
### Session-5 Novel Therapeutics Target inCancer

**Restoration of Tumour Suppression to Treat wt and Mutant p53 Hormone Related Cancers**
Ygal Haupt, Peter MacCallum Cancer Centre, Melbourne, Australia

**Functional Genomic Approaches to Identify new Wnt/b-catenin Regulators in Colorectal Cancer**
Ron Firestein, Cancer Centre at Hudson Institute, Monash University, Melbourne, Australia

**Ophiobolin A: A Promising Antiglioblastoma Agent**
Alexander Kornienko, Texas State University, TX, USA

**Investigation of miRNA and mRNA Co-expression Network in Ependymoma**
Tao Huang, Chinese Academy of Sciences, China

**Coffee Break**

### Session-6 Cancer Immunotherapy

**Immune Landscape Sculptured by the Peritoneal Microenvironment that supports Metastases arising from Colorectal Primary Tumours**
Robert G. Ramsay, Peter MacCallum Cancer Centre, Melbourne, Australia

**Immunotherapy of Solid Tumor with the Third Generation TCR-T**
Yi Li, Guangzhou Institutes of Biomedicine and Health, China

**Deciphering the Role of CD70/CD27 in Oncology**
Julie Jacobs, Scientist, Argenx Inc., Belgium

**Cancer Immunotherapy by Targeting TGF-β/Smad3**
Guangyu Lian, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong

**Distribution and Functions of CD39+Γδ Tregs Infiltrated in the Microenvironment of Left/Right- Sided Colorectal Cancer**
Zhan Yang, Tianjin Medical University Cancer Institute and Hospital, China

**Lunch Break**

### Session-7 Tumor Microenvironment and Cancer Stem Cells

**Novel Nanomedicine Shuts Down Metabolic Cellular Cross-talk Which Reduces Fibrosis and Pancreatic Tumour Progression**
Phoebe Phillips, Prince of Wales Clinical School, UNSW Medicine NSW, Australia

**Targeting Cell-Cell Communication in Tumours and the Tumour Microenvironment**
Peter Janes, Olivia Newton-John Cancer Research Institute, Heidelberg, Australia
Proteomic Profiling of the Prostate Tumour Microenvironment Reveals LOXL2 as a Therapeutic Target
Natalie Lister, Monash University, Melbourne, Australia

The Prognostic Value of S100A10 in Cancer
Normastuti Adhini Tantyo, Indonesia International Institute for Life Sciences, Indonesia

Coffee Break

Session-8 Cancer Targeted Therapy

Regulation of the Hypoxia Transcription Factors by Ascorbate and Potential Implications for Cancer Patients
Gabi Dachs, University of Otago, Christchurch, New Zealand

Repurposing Flubendazole as a Small Molecule Inhibitor of Programmed Cell Death Protein-1
Levon M. Khachigian, University of New South Wales, Sydney, Australia

Discovery of Novel Targetable Pathways and Drug Molecules for Infant Acute Lymphoblastic Leukaemia
Klaartje Somers, Children’s Cancer Institute, Sydney, Australia

EDNRB Isoform 3 Confers Temozolomide Resistance in Human Melanoma Cells by Modulating Membrane Potential, Reactive Oxygen Species and Mitochondrial Ca2+
Long Cui, Guangzhou Women and Children’s Medical and The Chinese University of Hong Kong, Hong Kong

Longitudinal Association of Subjective Prospective and Retrospective Memory and Depression among Patients with Glioma
Xuan Zhang, Shandong University, China

Poster Presentations
Session-9  Cancer Genetics

**SMAD Proteins Directly Suppress PAX2 Transcription Downstream of Transforming Growth Factor Beta 1 Signalling in Renal Cell Carcinoma**  
Michael Eccles, University of Otago, Christchurch, New Zealand

**Pharmacologically Targetable Vulnerability in Prostate Cancer Carrying RB1-SUCLA2 Deletion**  
Chiaki Takahashi, Cancer Research Institute, Kanazawa University, Japan

**High Methylation of ZNF582/PAX1 in Cervical Cancer Affected Radio-chemo and Neoadjuvant Chemotherapy Sensitivity and Prognosis**  
Yuligh Liou, Xiangya Medical Laboratory, Central South University, China

**Clinical Application of Tube-chip Digital PCR for Accurate Detection of Gene Mutation in Cancer Patients**  
Xiwen Jiang, DAAN Gene Co., Ltd. of Sun Yat-sen University, China